Your browser doesn't support javascript.
loading
Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease.
van Trier, Tinka J; Snaterse, Marjolein; Hageman, Steven H J; Ter Hoeve, Nienke; Sunamura, Madoka; Moll van Charante, Eric P; Galenkamp, Henrike; Deckers, Jaap W; Martens, Fabrice M A C; Visseren, Frank L J; Scholte Op Reimer, Wilma J M; Peters, Ron J G; Jørstad, Harald T.
Afiliação
  • van Trier TJ; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Snaterse M; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Hageman SHJ; Department of Vascular Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
  • Ter Hoeve N; Capri Cardiac Rehabilitation Rotterdam, Max Euwelaan 55, 3062 MA Rotterdam, The Netherlands.
  • Sunamura M; Department of Rehabilitation Medicine, Erasmus Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
  • Moll van Charante EP; Capri Cardiac Rehabilitation Rotterdam, Max Euwelaan 55, 3062 MA Rotterdam, The Netherlands.
  • Galenkamp H; Department of Cardiology, Sint Franciscus Gasthuis, Kleiweg 500, 3045 PM Rotterdam, The Netherlands.
  • Deckers JW; Department of General Practice, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Martens FMAC; Department of Public and Occupational Health, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
  • Visseren FLJ; Department of Cardiology, Thoraxcenter, Erasmus Medical Centre, Dr. Molewaterplein 40, 3015 GD Rotterdam, The Netherlands.
  • Scholte Op Reimer WJM; Department of Cardiology, Deventer Hospital, Nico Bolkesteinlaan 75, 7416 SE Deventer, The Netherlands.
  • Peters RJG; Department of Vascular Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.
  • Jørstad HT; Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Eur J Prev Cardiol ; 30(7): 601-610, 2023 05 09.
Article em En | MEDLINE | ID: mdl-36757680
ABSTRACT

BACKGROUND:

Most patients with atherosclerotic cardiovascular disease remain at (very) high risk for recurrent events due to suboptimal risk factor control.

AIMS:

This study aimed to quantify the potential of maximal risk factor treatment on 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events in patients 1 year after a coronary event. METHODS AND

RESULTS:

Pooled data from six studies are as follows RESPONSE 1, RESPONSE 2, OPTICARE, EUROASPIRE IV, EUROASPIRE V, and HELIUS. Patients aged ≥45 years at ≥6 months after coronary event were included. The SMART-REACH score was used to estimate 10-year and lifetime risk of recurrent atherosclerotic cardiovascular events with current treatment and potential risk reduction and gains in event-free years with maximal treatment (lifestyle and pharmacological). In 3230 atherosclerotic cardiovascular disease patients (24% women), at median interquartile range (IQR) 1.1 years (1.0-1.8) after index event, 10-year risk was median (IQR) 20% (15-27%) and lifetime risk 54% (47-63%). Whereas 70% used conventional medication, 82% had ≥1 drug-modifiable risk factor not on target. Furthermore, 91% had ≥1 lifestyle-related risk factor not on target. Maximizing therapy was associated with a potential reduction of median (IQR) 10-year risk to 6% (4-8%) and of lifetime risk to 20% (15-27%) and a median (IQR) gain of 7.3 (5.4-10.4) atherosclerotic cardiovascular disease event-free years.

CONCLUSIONS:

Amongst patients with atherosclerotic cardiovascular disease, maximizing current, guideline-based preventive therapy has the potential to mitigate a large part of their risk of recurrent events and to add a clinically important number of event-free years to their lifetime.
Patients with heart disease are at high risk of new cardiac events. This study amongst 3230 patients who had a heart attack or received a stent or bypass surgery shows missed potential for healthy life after a heart attack. The average age of study patients was 61 years, and 24% were women. At 1 year after the cardiac event, nearly one in three (30%) continued smoking, 79% were overweight, 45% reported insufficient physical activity, 40% had high blood pressure, and 65% had a too high LDL ('bad') cholesterol. We calculated that adherence to lifestyle advice and medications could on average halve the risk for another heart attack and add over 7 healthy years of life after a heart attack. This highlights the importance of healthy lifestyle and medication adherence after a heart attack. Key

finding:

• adherence to lifestyle advice and medications could add over 7 healthy years of life after a heart attack.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Aterosclerose Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Eur J Prev Cardiol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Aterosclerose Tipo de estudo: Diagnostic_studies / Etiology_studies / Guideline / Risk_factors_studies Limite: Female / Humans / Male Idioma: En Revista: Eur J Prev Cardiol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Holanda